DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Cabaletta - 3 Jim Cramer - 2 I'm - 1 It's - 1 I've - 1 Powell - 1 Marinus - 1 Biomea - 1
Top related locs:
Cabaletta 1H24
Top related orgs:
Citi - 2 Regions - 1 Powell Industries - 1 BlackRock - 1 Financial - 1 Marathon - 1 Federal Reserve - 1 CNBC Pro - 1

Search resuls for: "Cabaletta"


6 mentions found


☆ Cramer's Lightning Round: 'You should own' BlackRock
  + stars: | 2024-03-05 | by ( Julie Coleman | ) www.cnbc.com   time to read: +2 min
Stock Chart Icon Stock chart icon VICI Properties' year-to-date stock performance. Stock Chart Icon Stock chart icon Generac's year-to-date stock performance. Stock Chart Icon Stock chart icon Cabaletta Bio's year-to-date stock performance. Stock Chart Icon Stock chart icon Portillo's year-to-date stock performance. Stock Chart Icon Stock chart icon BlackRock's year-to-date stock performance.
Persons: I'm, Cabaletta, It's, I've, Powell Organizations: Regions, Powell Industries, BlackRock
☆ Lightning Round: Portillos is an 'overvalued company', says Jim Cramer
  + stars: | 2024-03-05 | by ( Jim Cramer | ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Portillos is an 'overvalued company', says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: VICI Properties, Generac, Cabaletta, Regions Financial, Marathon Digital, Portillos and more.
Persons: Jim Cramer Organizations: Financial, Marathon Locations: Cabaletta
☆ Analysts love these biotech stocks, giving 4 more than 100% upside
  + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.
Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals
☆ Lightning Round: The properties Enbridge got from Dominion were 'absolutely fantastic', says Jim Cramer
  + stars: | 2023-09-12 | by ( Jim Cramer | ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: The properties Enbridge got from Dominion were 'absolutely fantastic', says Jim Cramer'Mad Money' host Jim Cramer weighs in on stocks including: Magellan Midstream Partners, Cabaletta Bio, Edwards Lifesciences, International Flavors and Fragrances, CVS, Enbridge and Honeywell.
Persons: Enbridge, Jim Cramer, Cabaletta, Edwards Lifesciences Organizations: Dominion, Magellan Midstream Partners, Honeywell
☆ This little-known biotech stock has 'blockbuster potential,' says Citi
  + stars: | 2023-09-05 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +2 min
Autoimmune disease drugmaker Cabaletta Bio could soon have a multibillion-dollar product on its hands, according to Citi. Analyst Samantha Semenkow initiated research coverage with a buy rating on Cabaletta shares. Last October, the biotech firm obtained an exclusive, worldwide license for its autoimmune disease therapy CABA-201. The treatment is a CD19-directed chimeric antigen receptor modified T-cell therapy (CART), a treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. "In our view, the risk/reward is favorable into initial CABA-201 clinical data in 1H24."
Persons: Samantha Semenkow, Semenkow, Cabaletta, Morgan Stanley, Cowen, — CNBC's Michael Bloom Organizations: Citi, Evercore ISI Locations: 1H24
☆ TipRanks reveals the top 10 health care sector analysts of the past decade
  + stars: | 2023-05-21 | by ( Tipranks.Com Staff | ) www.cnbc.com   time to read: +5 min
TipRanks leveraged its Experts Center tool to recognize the ones with a high success rate. We also analyzed each stock recommendation made by health care sector analysts in the past decade. TipRanks' algorithms calculated the statistical significance of each rating, average return and the analysts' overall success rate. The buy recommendation generated a return of 397.9% from May 12, 2020 to May 12, 2021. Boris Peaker - TD CowenBoris Peaker has the 10th spot on the list, with a success rate of 47%.
0 next >>
Total: 6